KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Raw Materials: 2012-2025

Historic Raw Materials for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Sep 2025 value amounting to $57.0 million.

  • Supernus Pharmaceuticals' Raw Materials rose 392.51% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year increase of 392.51%. This contributed to the annual value of $11.1 million for FY2024, which is 31.63% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Raw Materials of $57.0 million as of Q3 2025, which was up 576.90% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Raw Materials peaked at $57.0 million during Q3 2025, and registered a low of $7.3 million during Q4 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Raw Materials averaged around $20.0 million, with its median value being $16.3 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Raw Materials plummeted by 73.50% in 2022 and then spiked by 392.51% in 2025.
  • Supernus Pharmaceuticals' Raw Materials (Quarterly) stood at $7.3 million in 2021, then skyrocketed by 238.84% to $24.8 million in 2022, then plummeted by 34.43% to $16.3 million in 2023, then crashed by 31.63% to $11.1 million in 2024, then surged by 392.51% to $57.0 million in 2025.
  • Its Raw Materials stands at $57.0 million for Q3 2025, versus $8.4 million for Q2 2025 and $8.7 million for Q1 2025.